Mattia Galli/LinkedIn
Nov 2, 2025, 05:36
Mattia Galli on Use of Genetic Testing to Guide the Choice of Antiplatelet Drugs
Mattia Galli, Assistant Professor at Sapienza University of Rome, Associate Editor of European Heart Journal, shared on LinkedIn:
”Growing interest in Rome in the use of genetic testing to guide the choice of antiplatelet drugs.
Is the time finally ripe for cardiology to move towards precision drug therapy?
A wonderful meeting and stimulating discussion with colleagues from one of Rome’s most important hospitals, in a session moderated by some of the “teachers” I had the pleasure of meeting during my specialization course.
Francesco Burzotta, Gaetano Antonio Lanza.”
Stay updated with Hemostasis Today.
-
Oct 6, 2026, 05:52David Esposito: Can Standard Ultrasound Detect May Thurner Syndrome?
-
Oct 6, 2026, 04:33Hessam Kakavand: Rethinking Thrombotic Risk in Modern Cancer Therapy
-
Oct 6, 2026, 04:07Moussa Zein Aldine: Acute Coronary Syndrome Every Minute Matters
-
Oct 6, 2026, 03:13Patrick Taylor: Glow Stack Trend What the Evidence Really Shows
-
Oct 6, 2026, 02:59Preventing Hospital Associated Venous Thromboembolism – Thrombosis Canada
-
Oct 6, 2026, 02:42Treatment of Iron Deficiency With and Without Anemia – American Society of Hematology
-
Oct 6, 2026, 02:36Mouna Sassi: When Clinical and Laboratory Perspectives Meet in Thrombosis Care
-
Oct 6, 2026, 02:35Lucia Stefanini: Platelet Dysfunction and Oxidized Phospholipids in MASLD
-
Oct 6, 2026, 02:18Pablo Corral: Association of Lp(a) With Coronary Atherosclerosis and CV Events